AZNAstraZenecaRunning, no new patients
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
Non-Small Cell Lung Cancer
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Nov 2022, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 3
- Patients
- 825 (final count)
- Started
- Dec 6, 2018
- Main results expected
- Nov 10, 2022
- Fully finished
- Sep 11, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Pathological Complete Response (pCR) in modified intent-to-treat (mITT) population
Measured over: Up to approximately 15 weeks after randomization
Event-Free Survival (EFS) in modified intent to treat (mITT) population
Measured over: Up to 5.5 years after first patient randomized.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2022-11-10, no fading
Raw record changes
- none yet
Trial ID NCT03800134 · record last updated 2025-06-11 · checked 2026-11-09 15:47 UTC